Funding boost for Australian disease detection centre
This article was originally published in Clinica
The Australian Biosecurity Co-operative Research Centre (AB-CRC) targets early disease detection and identification with a number of innovative products, including implantable chips, hand-held devices and satellite information systems. Over the next seven years it is likely to attract more than Aus$8m (US$5.6m) in external funding for further collaborative and multidisciplinary research and education programme, it claims.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.